PBAC's latest decision on Simeprevir: Recommended with restriction (2016). Considered for Treatment of chronic hepatitis C infection in treatment naïve and treatment-experienced patients.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
4
first 2014
Submissions
4
2014 → 2016
Eligible population
Treatment naïve and treatment-experienced patients with chronic hepatitis C infection.
Therapy area
Hepatology
Line of therapy
Any
Evidence base
Other
Economic model
Not modelled
ICER note
This is an administrative/listing change application with no new economic evaluation. The PBAC's March 2015 advice noted the drug was no longer cost-effective at its listed price compared to newer interferon-free treatments.
Submission history
Jul 2014: Recommended with restriction · Authority Required
Jul 2015: Recommended with restriction · Authority Required
Nov 2015: Recommended with restriction · Authority Required
Mar 2016: Recommended with restriction · Authority Required